

ONCOTYPE MAP™ PAN-CANCER TISSUE TEST

RAPID COMPREHENSIVE GENOMIC PROFILING TO AID THERAPY SELECTION

Every day matters. Why wait?

Oncotype MAP Pan-Cancer Tissue test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days to guide timely treatment decisions, usually before the next follow-up visit.

Utilizing next generation sequencing (NGS) and a broad array of immunohistochemical (IHC) stains and panels, the Oncotype MAP Pan-Cancer Tissue test identifies clinically-relevant genomic alterations from patient specimens as small as 3 mm² of tissue or 2-3 slides[†] allowing you to identify appropriate patient therapy based on tumor characteristics.

Results are provided in an easy-to-interpret report with NCCN® actionable indications for therapy, along with potential evidence-based therapies and clinical trials, to guide treatment options for a breadth of solid tumor types.



Answers you need at the speed your patients deserve



Fast

- Results reported in 3-5 business days**
- Quantity Not Sufficient (QNS) results typically reported within 48 hours



Comprehensive

- 257 genes, 11 select fusions
- 22 IHC stains including PD-L1 (22C3, SP142)
 - 25+ disease-specific panels
- Copy number variants, tumor mutation burden, microsatellite instability, and protein expression.



Actionable

- 100+ therapies, 45+ combination therapies, 650+ clinical trials
- NCCN Compendium recommendations



Accurate

- FNA and FFPE samples as small as 3 mm² with ≥15% tumor content
- >99% sensitivity for SNVs and Indels, detection down to ≥7.5% mutant allele frequency (MAF) with >99% specificity*

Oncotype MAP Pan-Cancer Tissue test helps guide therapy selection for today and captures emerging markers that may find their way into guidelines tomorrow.

**Order now for your patients
with solid tumors**

Oncotype MAP™ Pan-Cancer Tissue Test Markers

Immunohistochemistry										
Single IHC stains		Tumor-specific Panels								
ALK	PD1	Anal Carcinoma: PD-L1 (22C3), PD-1, TS, TUBB3				MMR: MLH1, MSH2, MSH6, PMS2				
AR	PD-L1 (22C3)	Appendix: HER2, PD-L1 (22C3), TOPI, PTEN				Neuroendocrine: PD-L1 (22C3), MGMT, PTEN, TP				
CAIX	PD-L1 (SP142)	Bladder: PD-L1 (22C3), PD-L1 (SP142), hENTI, TUBB3				NSCLC: PD-L1 (22C3), ALK, PD-L1 (SP142), PTEN, TS				
ER	PMS2	Bone Cancer: TOPI, MGMT, CAIX, HENTI				Ovarian: ER, HER2, TOPI, TUBB3				
hENTI	PR	Breast: AR, PD-L1(SP142), PD-L1 (22C3), TP				Pancreatic: hENTI, PTEN, TP, TOPI				
HER2	PTEN	CNS/Brain Cancers: MGMT, CAIX, TUBB3, TOPI				Penile Cancer: PD-L1 (22C3), TP, CAIX, TUBB3				
IDO	ROSI	Cervical: PD-L1 (22C3), CAIX, HENTI, TOPI				Prostate: AR, PTEN, TUBB3, PD-L1 (22C3)				
MET	TOPI	Colorectal: HER2, PD-L1 (22C3), TOPI, PTEN, TS				Sarcoma: CAIX, TUBB3, TOPI, MGMT				
MGMT	TP	Gastric/Esophageal: HER2, PD-L1 (22C3), PTEN, TS				SCLC: PD-L1 (22C3), TOPI, MGMT				
MLH1	TRKpan	GIST: PD-L1 (22C3), MET				Small Bowel: TOPI, CAIX, TUBB3, hENTI				
MMR (4 IHC)	TS	Head and Neck: PD-L1 (22C3), CAIX, TUBB3, PTEN				Testicular Cancer: PD-L1 (22C3), TUBB3, hENTI				
MSH2	TUBB3	Head and Neck Salivary Gland: HER2, AR, CAIX, PTEN				Thyroid: PD-L1 (22C3), ALK, TUBB3, CAIX				
MSH6		Hepatobiliary/Cholangiocarcinoma: hENTI, HER2, TP, PD-L1 (22C3)				Thymoma/Thymic Carcinoma: PD-L1 (22C3), TUBB3, hENTI, TS				
		Hepatobiliary/Gallbladder: hENTI, HER2, PD-L1 (22C3), TOPI				Uterine: PD-L1 (22C3), HER2, MGMT, TUBB3				
		Hepatobiliary/Hepatocellular: hENTI, PD-L1 (22C3), CAIX, MET				Uveal Melanoma: PD-L1 (22C3), MGMT, TUBB3				
		Kidney: PD-L1 (22C3), MET, CAIX, hENTI				Vulvar Cancer: PD-L1 (22C3), CAIX, TUBB3, hENTI				
		Melanoma: PD-L1 (22C3), MGMT, PTEN, TUBB3				Other Solid Tumors: PD-L1 (22C3), HER2, TOPI, PTEN, TS				
		Mesothelioma: PD-L1 (22C3), TS, hENTI, TUBB3								
257 NGS Gene Panel										
ABCB1	AREG	BUB1B	CYP19A1	EWSR1	GAS6	KEAP1	MYC	PIK3R1	RPTOR	TGFB2
ABCC1	ARID1A	CALR	CYP11A1	EZH2	GATA3	KIT	MYCN	PIM1	RRM1	TGFB3
ABCC2	ARID1B	CBL	CYP2D6	FAM175A	GLI1	KRAS	MYO1	PLCB4	SDHB	TGFBR1
ABL1	ARID2	CCND1	CYP3A4	FANCA	GNA11	MAF	NBN	PLCG1	SDHC	TGFBR2
ACVR1	ATM	CCND2	CYSLTR2	FANCC	GNAQ	MAP2K1	NF1	PMS2	SETD2	TNFAIP3
ACVR1B	ATR	CCND3	DCK	FANCD2	GNAS	MAP2K2	NF2	POLD1	SF3B1	TNK1
ACVR2A	ATRX	CCNE1	DDR2	FANCE	GSTP1	MAP3K1	NFE2L2	POLE	SMAD1	TOP2A
ACVR2B	AURKA	CD274	DICER1	FANCF	HAMP	MAPK1	NOTCH1	PP2R1A	SMAD2	TP53
ACVRL1	AURKB	CDA	DNMT3A	FANCG	HDAC2	MAPK3	NOTCH2	PTCH1	SMAD4	TSC1
ADAMTS1	AXIN1	CDC73	EGFR	FANCM	HGF	MAPKAPK5	NOTCH3	PTEN	SMAD5	TSC2
ADAMTS6	AXL	CDH1	EMSY	FAT1	HNF1A	MDM2	NPM1	PTPN11	SMAD9	TSHR
ADAMTS9	B2M	CDK4	EP300	FBXW7	HRAS	MDM4	NRAS	RAD50	SMARCA4	TYMS
ADAMTS16	BAP1	CKD6	EPCAM	FCGR2A	HSD3B1	MED12	NTRK1	RAD51C	SMARCB1	VEGFA
ADAMTS18	BARD1	CDK12	EPHA5	FGD4	IDH1	MEN1	NTRK2	RAD51D	SMO	VHL
ADAMTSL1	BCOR	CDKN2A	EPHA7	FGF3	IDH2	MET	NTRK3	RAF1	SOCS1	WT1
AKT1	BMP6	CHEK1	ERBB2	FGF4	IGF1R	MGMT	PALB2	RB1	SPOP	XRCC1
AKT2	BMPR1A	CHEK2	ERBB3	FGFR1	IKZF1	MLH1	PBRM1	RBM10	STAG2	YES1
AKT3	BMPR1B	CHFR	ERBB4	FGFR2	IL6R	MPL	PDCD1LG2	RECQL	STAT3	
ALK	BNIP3	CHKA	ERCC1	FGFR3	JAK1	MRE11A	PDGFRA	RET	STAT5A	
AMER1	BRAF	CIC	ERCC2	FGFR4	JAK2	MSH2	PDGFRB	RHEB	STAT5B	
APC	BRCA1	CREBBP	ERCC3	FLT3	JAK3	MSH6	PIK3CA	RICTOR	STK11	
APLNLR	BRCA2	CSF1R	ERRF1	FLT4	KDM5C	MTHFR	PIK3CB	RIT1	SUFU	
AR	BRIP1	CTLA4	ESR1	FOXL2	KDM6A	MTOR	PIK3CD	RNF43	TERT-p	
ARAF	BTK	CTNNB1	ESR2	FUBP1	KDR	MUTYH	PIK3CG	ROS1	TGFB1	

Genetic Structures Tested: Single nucleotide variants (SNVs) and insertions/deletions in coding regions of genes listed above; UTRs and splice junctions when actionable (e.g. MET exon 14 skipping and EGFRvIII). MSI; mutation burden (SNV's, insertions, deletions) based on -1 megabase; select fusions involving ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, RET, ROS1, NTRK1, NTRK2, NTRK3 (ETV6); and copy number variants.

Turnaround time is based on when sample is received. Mutation calls may not be available from some regions due to pseudogenes or sequence context. Select IHCs may not be run if already performed within the last six months unless indicated in the notes section. HER2 equivocal by IHC will be reflexed to FISH testing in select tumor types. Reflex testing will exceed standard turnaround time for results. MMR includes the following IHCs: MLH1, MSH2, MSH6, PMS2.



Clinical Laboratory Improvement Amendments



Contact Paradigm Diagnostics/Exact Sciences
 1-866-662-6897 | oncotypemap@exactsciences.com
www.oncotypemap.com

About Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences helps people get the answers they need to make more informed decisions across the cancer continuum. Building on the success of the Cologuard and Oncotype DX tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Through an innovative, rigorous approach, and with the support of visionary collaborators, we're helping advance the fight against cancer.

References:

- * Data on file, in-house assay optimization protected by trade-secret/patent regulations.
- † Turnaround time is based on sample receipt.
- ‡ Morris S, Subramanian J, Gel E, Rungger G, Thompson E, Mallery D, et al. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform. PLoS ONE. (2018); 13(4): e0196556. <https://doi.org/10.1371/journal.pone.0196556>.

NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Oncotype MAP™ and Oncotype MAP™ Pan-Cancer Tissue Test are trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. ©2020 Genomic Health, Inc. All rights reserved. EXS50041